Use of PDT to inhibit intimal hyperplasia

Details Use of PDT to inhibit intimal hyperplasia Use of PDT to inhibit intimal hyperplasia

2000-11-17

2003-08-19

Doerrler, William C. (Department: 3744)

Surgery

Diagnostic testing

Measuring or detecting nonradioactive constituent of body...

C600S342000, C604S021000, C606S015000

Reexamination Certificate

active

06609014

ABSTRACT:

TECHNICAL FIELD
The invention relates to the use of low-dose photodynamic therapy (PDT) to inhibit or reduce stenosis caused by intimal hyperplasia (IH) in blood vessels. In particular, the treatment of IH at an anastomosis of a graft or conduit providing vascular access, such as an arteriovenous (AV) fistula, is disclosed. The invention also relates to inhibiting or reducing the smooth muscle cell (SMC) growth component of IH by low-dose PDT.
BACKGROUND ART
Patients with chronic renal failure in the United States number approximately 2 million, with 220,000 receiving dialysis therapy as of 1998 (1). The current annual increase in the number of patients receiving chronic hemodialysis is 6 to 7 percent due to acceptance of older candidates, patients living longer, the scarcity of transplantable kidneys, and the loss of transplanted kidneys, returning people to dialysis (1,2). Long-term dialysis requires provision of safe and reliable vascular access, often in the form of an arteriovenous (AV) fistula or an AV conduit, usually made of polytetrafluoroethylene (PTFE)(3,4,5). Unfortunately the failure rate of access fistulae can be as high as 60% at one year, with the mean time from insertion to first repair being only 10 months (6,7).
The primary cause of AV fistula or AV conduit loss or failure is stenosis caused by intimal hyperplasia (IH), which includes a smooth muscle cell (SMC) growth component, in the graft at the venous anastomosis or the distal vein (8). IH leads to formation of a thickened fibromuscular layer between the vein endothelium and the inner elastic lamina (IEL). Excessive thickening of the intima can lead to luminal narrowing and reduction of blood flow to such an extent that thrombosis occurs (9). This early failure represents the destruction of a useful access site, ultimately compromising the life of a patient dependent on dialysis (10). Mortality among dialysis patients, although slowly declining, remains at 20 percent per year (11).
Considerable research has aimed at pharmacological intervention to prevent intimal hyperplasia, and although a number of agents have shown great promise in animal or angioplasty models—very few have been shown to be of any benefit in hemodialysis patients (12). Photodynamic therapy (PDT) is an approach that has been investigated for the inhibition of intimal hyperplasia in other settings (see U.S. Pat. No. 5,422,362, which is hereby incorporated by reference). PDT generally involves administration of an inert photosensitizer (PS) that becomes activated by a specific wavelength of light. Once activated, PS produces toxic oxygen species that cause cell death by affecting cell membranes and subcellular organelles (13) or, when used in low doses, modulate cell behavior (14,15,16).
Intimal hyperplasia has been successfully inhibited in animal models involving balloon-catheter induced injury to arteries by PDT (17,18), and human SMCs isolated from arteries and veins have been shown to be susceptible to PDT (19,20). LaMuraglia et al. have investigated the efficacy of PDT to reduce vein graft IH. Although their “ex vivo” PDT protocol led to suppression of IH in the body of the vein graft, it did not affect IH at the anastomosis of the vein graft to an artery (21).
DISCLOSURE OF THE INVENTION
The present invention relates to methods of using photodynamic therapy (PDT) to prevent, treat, inhibit or reduce intimal hyperplasia (IH) in blood vessels in vivo. In particular the methods may be applied to the in vivo prevention and/or treatment of stenosis in an anastomosis, such as at those of an arteriovenous (AV) fistula or conduit. The methods of the invention may be used in any vein, artery, and/or vascular graft, and include the combined use of a photosensitizer (PS) and radiation sources for irradiation that offer advantages over previous methods of treating blood vessels and anastomoses, including those of AV fistulae or conduits. The PS may be delivered systemically, locally, and even directly into the lumen of the blood vessel tissue to be treated. Local delivery of the PS provides a high local concentration while reducing the likelihood of transient skin photosensitivity that might follow systemic PS administration.
Following, or simultaneous with, PS administration, treatment with radiation absorbed by the PS may be performed by any means, including direct irradiation of the anastomosis, the blood vessel tissue containing it, or a larger area containing the anastomosis and other tissues, or extraluminal irradiation from the adventitia using ambient light or a flexible patch diffuser. In a preferred embodiment, the radiation is applied via a flexible patch diffuser that can be wrapped around the blood vessel. This permits the use of lower light intensities that inhibit IH inhibit (IH) without compromising the blood vessel's wall.


REFERENCES:
patent: 5015584 (1991-05-01), Brysk
patent: 5171749 (1992-12-01), Levy et al.
patent: 5192312 (1993-03-01), Orton
patent: 5200400 (1993-04-01), Teramoto et al.
patent: 5298018 (1994-03-01), Narciso, Jr.
patent: 5422362 (1995-06-01), Vincent et al.
patent: 5834503 (1998-11-01), Kelly et al.
patent: 5880145 (1999-03-01), Sternberg et al.
patent: 5929105 (1999-07-01), Sternberg et al.
patent: 6235767 (2001-05-01), Kelly et al.
patent: 6366719 (2002-04-01), Heath et al.
patent: 906758 (1999-04-01), None
patent: WO 0021562 (2000-04-01), None
patent: WO 0124825 (2001-04-01), None
Adili, F. et al. (1998). “Photodynamic therapy with local photosensitizer delivery inhibits experimental intimal hyperplasia”Lasers In Surgery and Medicine23(5):263-73.
Adili, F, et al. (1999). “Significance of dosimetry in photodynamic therapy of injured arteries: classification of biological responses”Photochemistry and Photobiology70(4):663-8.
Burbridge, G.E., et al. (1976). “Late complications and results of bovine xenografts”Trans Am Soc Artif Intern Organs, 22, 377-81.
Byrne, C., et al. (1994). “Effect of age and diagnosis on survival of older patients beginning chronic dialysis.”Jama, 271, 34-6.
Dartsch, P.C., et al. (1990). “Responses of cultured smooth muscle cells from human nonatherosclerotic arteries and primary stenosing lesions after photoradiation: implications for photodynamic therapy of vascular stenoses”J Am Coll Cardiol, 15, 1545-50.
Dilley, R.J., et al. (1988). “A review of the histologic changes in vein-to-artery grafts, with particular reference to intimal hyperplasia”Arch Surg, 123, 691-6.
Diskin CJ, S.T., et al. (1993). “Pharmacological intervention to prevent intimal hyperplasia”In Vascular Access For Hemodialysis, vol. III. WL Gore and Associates, Inc. and Precept Press, Inc., pp. 41-73.
Dougherty, T.J. (1987). “Photosensitizers: therapy and detection of malignant tumors”Photochem Photobiol, 45, 879-89.
Excerpts from the United States Renal Data System Annual Report. (1998)American J. Kidney Dis., 32, S9-S141.
Hsiang, Y.N., et al. (1995). “Dosage and timing of photofrin for photodynamic therapy of intimal hyperplasia”Cardiovascular Suurgery3(5):489-94.
Humphries AL, et al. (1989). “Alternative plans for vascular access for hemodialysis”In . Vascular Access for Hemodialysis vol. I. WL Gore and Associates, Inc. and Pluribus Press, Inc.
Hunt, D.W., et al. (1999). “Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes”Immunopharmacology, 41, 31-44.
Hurt, A.V., et al. (1983) “Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study.”Am J Surg, 146, 844-7.
Kaplan MP, et al. (1989). “An analysis of early (two week) failure of vascular access”In Vascular Access for Hemodialysis, vol. III. WL Gore and Associates, Inc. and Pluribus Press, Inc., pp. 114-123.
LaMuraglia, G.M., et al. (1994). “Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects”J Vasc Surg, 19, 321-9; discussion 329-31.
LaMuraglia, G.M., et al. (1995). “Photodynamic therapy of vein grafts: suppression of intimal hyperplasia of the vein graft but not the anastomosis”J Vasc Surg, 21, 882-90; discussion 889-90.
L

Affiliated with

Also associated with

Rating

Use of PDT to inhibit intimal hyperplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of PDT to inhibit intimal hyperplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of PDT to inhibit intimal hyperplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3100052